Capricor sues Nippon Shinyaku over pricing dispute for Duchenne cell therapy candidate
read at Endpoints ↗Negative
Capricor Therapeutics announced it has filed a lawsuit against its Japanese partner Nippon Shinyaku.
The suit alleges a flaw in the pricing terms of the distribution and commercialization agreement for deramiocel, Capricor’s cell therapy candidate targeting Duchenne muscular dystrophy.
Capricor says the dispute threatens the planned launch of deramiocel and seeks resolution of the pricing issue.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prep”
read at Endpoints ↗83 words · retrieved May 8
comments(0)
5-min edit window · permanent after that